|
Session 104
Poster Abstracts
Selection, Evolution and Persistence of Drug Resistance
Wednesday, 1:30 - 3:30 pm
Poster Hall |
| 614 |
Development of a Cell Culture Assay to Predict which Non-Nucleoside Reverse Transcriptase Inhibitor-resistant Variants Will Emerge during Clinical Therapy
Carrie Dykes* and L Demeter
Univ of Rochester, Sch of Med and Dentistry,NY, US |
615
 |
Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pre-treated Patients Remaining on a Stable Partially Suppressive Regimen
Hiroyu Hatano*1, P Hunt1, J Weidler2, E Coakely2, R Hoh1, T Liegler1,3, J Martin1, and S Deeks1
1Univ of California, San Francisco, US; 2Monogram Biosci, South San Francisco, CA, US; and 3Gladstone Inst of Virology and Immunology, Univ of California, San Francisco, US |
| 616 |
Archived NNRTI-resistant HIV-1 in the Resting CD4+ T Cell Reservoir of Patients with a Previous History of K103N or Y181C Mutations
Megan Wind-Rotolo*, C Haggerty, J Siliciano, P Kwon, L Cranmer, R Nettles, and R Siliciano
Johns Hopkins Univ, Baltimore, MD, US |
| 617 |
Acquisition and Archiving of Non-Nucleoside Reverse Transcriptase Inhibitor-resistant HIV-1 Variants during Mother-to-Child Transmission in US-born Infants
Deborah Persaud*1, P Palumbo2, C Ziemniak1, P Havens3, E Chadwick4, and Pediatric AIDS Clin Trials Group P1030 Team
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Univ of Med and Dentistry of New Jersey, Newark, US; 3Children's Hosp of Wisconsin, Milwaukee, US; and 4Northwestern Univ Children's Memorial Hosp, Chicago, IL, US |
| 618 |
Drug Resistance in Plasma and Genital Compartments among Viremic, Multi-drug-experienced Men and Women
David Katzenstein*1, M Winters1, S Fiscus2, D Bettendorf3, R Kantor4, M Wantman3, S Cu-Uvin4, R D’aquila5, L Frenkel6, R Coombs6, and AIDS Clin Trials Group 5077
1Stanford Univ, CA, US; 2Univ of North Carolina at Chapel Hill, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Brown Univ, Providence, RI, US; 5Vanderbilt Univ Sch of Med, Nashville, TN, US; and 6Univ of Washington, Seattle, US |
| 619 |
Effect of NRTI- and NNRTI-resistance Mutations on CTL Recognition
S Kaiser1, I Stahmer1, J Van Lunzen1, T Fenner2, T Eiermann1, C Möcklinghoff3, and Hans-Jürgen Stellbrink*4
1Univ Hosp Eppendorf, Hamburg, Germany; 2Fenner Lab, Hamburg, Germany; 3Roche, Grenzach-Wyhlen, Germany; and 4IPM Study Ctr, Hamburg, Germany |
620
|
Effect of HIV-1 Subtype on Genotypic Resistance to Protease Inhibitors in the United Kingdom
Philippa Easterbrook*, T Welz, and on behalf of the UK Collaborative Group on HIV Drug Resistance
King's Coll London Sch of Med, London, UK |
621
|
Stochastic Evolution of Drug-resistant Strains of HIV in Botswana
Raffaele Vardavas* and S Blower
David Geffen Sch of Med, Univ of California, Los Angeles Med Ctr, US |
622a
|
Improved Virologic Outcomes and Less HIV Resistance for HAART-experienced Substance Users Receiving Modified Directly Observed Therapy: Results from a Randomized Controlled Trial
Jennifer Mitty*1, D Mwamburi2, G Macalino3, A Caliendo4, L Bazerman5, and T Flanigan1
1Brown Univ, Providence, RI, US; 2Tufts Univ Sch of Med, Boston, MA, US; 3Tufts New England Med Ctr, Boston, MA, US; 4Emory Univ Sch of Med, Atlanta, GA, US; and 5Miriam Hosp, Providence, RI, US |
| 622b |
CD4-guided Scheduled Treatment Interruptions: Low Incidence of Resistance Mutations in the Staccato Trial
Jintanat Ananworanich*1, B Hirschel2, H Furrer3, S Ubolyam1, A Gayet-Ageron2, A Gayet-Ageron, S Yerly2, T Jupimai1, A Hill4, L Perrin2, K Ruxrungtham1,5, and the Staccato Study Group
1HIV Netherlands Australia Thailand Res Collaboration, Bangkok; 2Geneva Univ Hosp, Switzerland; 3Univ Hosp, Berne, Switzerland; 4Univ of Liverpool, UK; and 5Chulalongkorn Univ, Bangkok, Thailand |
|
